Mahamaya Lifesciences came to market through an SME IPO that opened on 11 November 2025 and closed on 13 November 2025, and the shares listed on 18 November 2025 on BSE SME. The price band was ₹108 to ₹114 per share and one lot was 1200 shares, so the minimum application was ₹1,36,800. The issue size was ₹70.44 crore. It combined a fresh issue of new shares with an offer for sale by existing shareholders.
Kfin Technologies Ltd was the registrar to the issue, and Oneview Corporate Advisors Pvt.Ltd was the lead manager.
As of 13 November 2025.
| Day |
|---|
| 1 |
| 2 |
| 3 |
Incorporated in 2002, Mahamaya Lifesciences Limited is engaged in manufacturing, registration, and export of the finest crop protection products and bio-products for crop & soil health management and to help the farming community for more productivity.
The company has developed considerable expertise in the manufacture of pesticide formulations and bulk products for Indian agrochemical companies and MNCs.It imports carefully researched molecules, gets them registered with the Central Insecticides Board, and sells them as technical and value-added formulations to domestic manufacturers and MNCs. The company has invested in global product registrations, with active markets including the Dominican Republic, Egypt, Ethiopia, Jordan, UAE, and Turkey, offering high-quality products and data support for registrations.
As described in the offer document.
| Metric | 30-Jun-25 | 31-Mar-25 | 31-Mar-24 | 31-Mar-23 |
|---|
Mr. Krishnamurthy Ganesan, Mrs. Lalitha Krishnamurthy, Mr. Prashant Krishnamurthy. Promoter holding 77.27% before the issue and 56.35% after.
Work out the listing gain for this SME IPO
If the retail portion is not fully subscribed, every valid application is allotted in full. If it is oversubscribed, SEBI's rules require that as many applicants as possible receive at least one lot, so the shares are allotted by a computerised lottery across all valid applications, one lot each, until the retail portion is exhausted. Applying for more lots does not improve your chance in a lottery; it only increases what you receive if the issue is under-subscribed.
The basis of allotment document, published by the registrar on the allotment date, states the ratio: for example, one applicant in seven received one lot.
Allotment status is published by the registrar on its website, searchable by PAN, application number or demat account, and also on the exchange's website. Allotted shares are credited to the demat account the day before listing, and blocked money for unsuccessful applications is released the same day. The Rupix app can check allotment status by PAN once the registrar publishes it.
Shares list within three working days of the issue closing. On listing day the exchanges run a special pre-open session from nine o'clock, during which orders are collected and an opening price is discovered from them; trading in the share begins after that, usually around ten. The opening price is the listing price that appears on this page once the issue has listed, and the listing gain or loss is the difference between it and the issue price.
For a mainboard issue, the share then trades in the normal way with the exchange's price band for a new listing. For an SME issue, shares trade in lots rather than one at a time, and the market can be thin, so selling on listing day is not always possible at the opening price. Capital gains on shares sold within a year of allotment are short-term and taxed at the short-term rate.
Mahamaya Lifesciences IPO was a ₹70.44 crore book-built issue, comprising a fresh issue of ₹64.28 crore and an offer for sale of ₹6.16 crore. It was priced at ₹108–₹114 per share with a lot size of 1,200 shares; the minimum retail application was 2,400 shares (₹2,73,600). The IPO was open from November 11 to November 13, 2025 and was subscribed 1.59x.
Shares listed on BSE SME on November 18, 2025 at ₹116, a 1.8% premium to the issue price of ₹114. Kfin Technologies Ltd is the registrar. Oneview Corporate Advisors Pvt. Ltd. is the book running lead manager.
The price band of Mahamaya Lifesciences IPO is ₹108 to ₹114 per share.
The lot size of Mahamaya Lifesciences IPO is 1200 shares.
The minimum investment for Mahamaya Lifesciences IPO is approximately ₹2,73,600 based on the upper price band.
The allotment date of Mahamaya Lifesciences IPO is Nov 14, 2025.
You can check Mahamaya Lifesciences IPO allotment status on the registrar or stock exchange websites using your PAN or application number after allotment. You can also check the Mahamaya Lifesciences IPO allotment status on Rupix for quick and easy access.
₹108 to ₹114 per share, against a face value of ₹10. Most applicants bid at the cut-off price, the top of the band, so that the application was valid whatever price the issuer finally fixed.
One lot was 1200 shares, and every application had to be a whole number of lots. At the top of the band that made the minimum application ₹1,36,800. After listing, SME shares also trade in lots rather than one share at a time.
₹1,36,800, for one lot of 1200 shares at the top of the price band. The amount was blocked in the applicant's bank account through ASBA or a UPI mandate while the issue was open, and released on the allotment date to applicants who were not allotted shares.
It opened on 11 November 2025 and closed on 13 November 2025.
The basis of allotment was published on 14 November 2025 by Kfin Technologies Ltd, and allotted shares were credited to demat accounts before listing.
The shares listed on 18 November 2025 on BSE SME.
The issue size was ₹70.44 crore. The fresh issue was 56,38,800 shares (aggregating up to ₹64.28 crore). The offer for sale was 5,40,000 shares (aggregating up to ₹6.16 crore).